DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that preclinical data from studies of the company’s selective effector cell activator (SECA™) immuno-oncology drug candidate, RDB 1450 (formerly referred to as RDB 1419), will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Pa., April 18-22, 2015. Based on the preclinical data for this program to date, Alkermes plans to initiate a phase 1 clinical study of RDB 1450 in the third quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
